

**Virginia's Department of Medical Assistance Services
Pharmacy and Therapeutics Committee Meeting**

*600 East Broad Street – 7th Floor Conference Rooms
Richmond, Virginia 23219*

Thursday, October 15, 2015 - 10:00 a.m.

Welcome and Comments from DMAS' Director

Cynthia B. Jones

Call to Order

Tim Jennings, Pharm.D., Chairman

Drug Utilization Review (DUR) Board Update

Avtar Dhillon, M.D., DMAS DUR Board

Magellan Health Update

Debbie Moody, R.Ph., Clinical Manager

Approval of Minutes From April 16, 2015 Meeting

P&T Committee Members

PDL Management

P&T Committee Members

• **PDL Phase II – New Drug Review**

- Acne Agents (Epiduo[®] Forte Topical Gel, Panoxyl[®] 3% Cream & adapalene lotion (generic for Differin[®])
- Androgenic (Natesto[™] Nasal Gel)
- Antifungals, Oral (Cresemba[®])
- Antifungals, Topical (naftifine - generic for Naftin[®] cream)
- Antimigraine Agents (almotriptan - generic for Axert[®])
- Antivirals Hepatitis C (Daklinza[®] & Technivie[™])
- Bone Resorption Suppression (risedronate - generic for Atelvia[™])
- Diabetes Hypoglycemics Insulins (Toujeo[®] Solostar[®])
- Multiple Sclerosis (Glatopa[®])
- Nonsteroidal Anti-Inflammatory Drugs (Tivorbex[™] & naproxen cream - generic for Naprelan[®])
- Platelet Aggregation Inhibitors (ASA/dipyridamole - generic for Aggrenox[®])
- Stimulants and Related Agents (Aptensio[®] XR)
- Topical Analgesic Agents and Anesthetics (DermacinRX[®] Lexitral topical cream)

• **PDL Phase I – Annual Review**

Antibiotic-Anti-Infective

- Antibiotics, Vaginal

Blood Modifiers

- Bile Salts
- Phosphate Binders

Cardiac Medications

- Angiotensin Modulators (*ACEs, ARBs, & combination products*)
- Angiotensin Modulators II (*Direct Renin Inhibitors & combination products*)
- Antihypertensives, Sympatholytics
- Beta Blockers (*includes combination products*)
- Calcium Channel Blockers (*includes dihydropyridine and non-dihydropyridine agents*)
- Lipotropics, Others (*includes Bile Acid Sequestrants, Cholesterol Absorption Inhibitor agent, Fibric Acid derivatives, Microsomal Triglyceride Transfer Protein Inhibitor, Oligonucleotide Inhibitors and Omega 3 agents*)
- Lipotropics, Statins
- Pulmonary Hypertension Agents (*Endothelin-1 agents, PDE-5 Inhibitors; Prostacyclin analogues, Prostacyclin Vasodilator, Soluble Guanylate Cyclase Stimulators*)

Central Nervous System

- Alzheimer's Agents
- Anticonvulsants
- Antidepressants, Other & SSRI
- Antipsychotics
- Sedative Hypnotics (includes other Hypnotics)

Dermatologic Agents

- Immunological Atopic Dermatitis
- Steroids, Topical

Endocrine & Metabolic Agents

- Growth Hormones
- Glucocorticoids, Oral
- Hereditary Angioedema (HAE)
- Progestins for Cachexia

Gastrointestinal

- Antiemetic/Antivertigo Agents
- H. Pylori Treatment
- Histamine-2 Receptor Antagonists (H-2RA)
- Gastrointestinal (GI) Motility, Chronic
- Proton Pump Inhibitors
- Ulcerative Colitis (oral and rectal)

Genitourinary

- BPH Agents (*includes Alpha Blockers, Androgen Hormone Inhibitors and Phosphodiesterase (PDE) 5 Inhibitor for BPH treatment*)
- Bladder Relaxants

Ophthalmics

- Antibiotic/Steroid Combinations
- Antibiotics
- Anti-Inflammatory Agents (*includes Ophthalmic NSAIDS & Corticosteroids*)
- Allergic Conjunctivitis (*includes Ophthalmic Antihistamines & Mast Cell Stabilizers*)
- Glaucoma Agents (*includes Alpha-2 Adrenergic, Beta-blockers, Carbonic Anhydrase Inhibitors, Prostaglandin Inhibitors*)

Respiratory

- Anti-Allergens, Oral
- Antibiotics, Inhaled
- Antihistamines Minimally Sedating
- Bronchodilators Long Acting Beta Adrenergics
- Bronchodilators Short Acting Beta Adrenergics
- COPD (*includes Anticholinergics, Bronchodilators and Phosphodiesterase 4 (PDE4) Inhibitors*)
- Cough & Cold Agents (Legend)
- Epinephrine, Self-Injected
- Glucocorticoids (*includes nebulized solutions, metered dose inhalers and combinations*)
- Intranasal Rhinitis (*includes Antihistamines and Corticosteroids*)
- Leukotriene Modifiers

Confidential Meeting (Pricing Information Discussion)	P&T Committee, DMAS & PS Staff Pursuant to 42 USC §1396r-8
PDL Recommendations and Vote	P&T Committee Members
Criteria Discussion of Phase II New Drugs*	P&T Committee Members
Criteria Discussion of PDL Phase I Drug Classes*	P&T Committee Members
Next Meeting – April 14, 2016	Tim Jennings, Pharm. D., Chairman

**Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.*

Oral Presentations: The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on *only* the drug classes in Phase I which are scheduled for review at the October meeting and new drugs in PDL Phase II listed on the Agenda. **All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:**

- PDL Phase I Annual Reviews – October 2014 to present
- New Drugs in PDL Phase I or II Drug Classes – October 2013 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 3 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. **Speakers must receive a confirmation number to verify the presentation is scheduled.**

Anyone interested in providing specific clinical information to the Committee at the meeting must submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send requested information to pdlinput@dmas.virginia.gov and dfmoody@magellanhealth.com by 5 p.m. EST on **Thursday, September 17, 2015.**

Written information/comments: The P&T Committee will also accept written comments for consideration. Please send statements to pdlinput@dmas.virginia.gov by 5 p.m. EST **Thursday, September 17, 2015.**